# Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-ResistantMycobacterium tuberculosis Isolates in Southwest of China

Authors: Y. Hu; L. Xu; Y. L. He; Y. Pang; N. Lu; J. Liu; J. Shen; D. M. Zhu; X. Feng; Y. W. Wang; C. Yang
Journal: BioMed Research International
 (2017)

---

## Abstract

This study aimed to investigate the prevalence of multidrug-resistant tuberculosis (MDR-TB) isolates resistant to the second-line antituberculosis drugs (SLDs) and its association with resistant-related gene mutations inMycobacterium tuberculosis (M.tb) isolates from Southwest of China. There were 81 isolates resistant to at least one of the SLDs among 156 MDR-TB isolates (81/156, 51.9%). The rates of general resistance to each of the drugs were as follows: OFX (66/156, 42.3%), KAN (26/156, 16.7%), CAP (13/156, 8.3%), PTO (11/156, 7.1%), PAS (22/156, 14.1%), and AMK (20/156, 12.8%). Therefore, the most predominant pattern was resistant to OFX compared with other SLDs (P<0.001). The results of sequencing showed that 80.2% OFX-resistant MDR-TB isolates containedgyrA mutation and 88.5% KAN-resistant isolates hadrrs mutations with the most frequent mutation being A1401G. These results suggest that improper use of SLDs especially OFX is a real threat to effective MDR-TB treatment not only in China but also in the whole world. Furthermore the tuberculosis control agencies should carry out SLDs susceptibility testing and rapid screening in a broader population of TB patients immediately and the SLDs should be strictly regulated by the administration in order to maintain their efficacy to treat MDR-TB.


---

## Body

## 1. Introduction

Tuberculosis (TB) remains a public threat to human health around the whole world; WHO estimates that, in 2015, 10.4 million people became ill with active TB and 1.4 million died from the disease, making it the world’s leading cause of death by a single infectious agent [1]. In China, there are about 1.1 to 1.5 million new TB cases per year [2]. During the 1990s, multidrug-resistant tuberculosis (MDR-TB), defined as resistant to at least isoniazid and rifampin, emerged as a threat to TB control [3, 4]. Globally, 480,000 new TB cases (3.9%) are MDR-TB in 2015 [1]. In China, the proportion of MDR-TB cases is growing dramatically, and national survey estimated that there were 110,000 cases of MDR-TB and 8,200 cases of XDR-TB [5]. MDR-TB treatment requires the use of second-line drugs (SLDs) that are less effective, more toxic, and costlier than first-line isoniazid- and rifampin-based regimens. Recent studies have suggested that resistance to SLDs has arisen as a new threat [6–8], leading to extensively drug-resistant tuberculosis (XDR-TB), which has been found in 117 countries/regions thus far [1], and even so-called totally drug-resistant tuberculosis [6, 9].There is a high incidence of TB in the Southwest of China. From 2014, local tuberculosis control agencies started the investigation of resistance to SLDs in MDR-TB isolates. Therefore this is the first report about the distribution characteristics of SLDs-resistant MDR-TB isolates and the main molecular mechanisms of SLDs resistance in this region. These results will provide a reference and basis for the development of rational MDR-TB chemotherapy regimen and the experience of MDR-TB control strategy inside and outside this region.


## 2. Materials and Methods

Ethical Approval. This study was approved by the Ethics Committee of the Chongqing Tuberculosis Control Institute. Patients enrolled in this study were given a subject information sheet, and all gave written informed consent to participate in this study.Patient Enrollment. 677 smear-positive tuberculosis patients who were registered at local tuberculosis control agencies between January 2015 and August 2016 from 39 Districts of Chongqing Municipality, China, were enrolled in this study. Demographic information was obtained by review of medical record. The isolates were transferred to Chongqing Tuberculosis Control Institute for further drug susceptibility testing. According to the drug treatment history, the MDR-TB cases were divided into 4 groups: the previously treated cases, previously treated failure cases, retreatment cases, and retreatment failure cases, based on the China TB control program implementation guide (2008). The previously treated cases represent the pulmonary tuberculosis patients, still sputum smear-positive at the end of 3-month treatment. The previously treated failure cases represent the previously pulmonary tuberculosis patients, still sputum smear-positive after the whole treatment (6 months) or treatment for 5 months. The retreatment cases are defined as pulmonary tuberculosis patients, who were once cured but relapsed or were treated more than 1 month but treatment interruption was longer than 2 months. And the retreatment failure cases are defined as retreated pulmonary tuberculosis patients, still sputum smear-positive after the whole treatment (9 months) or treatment for 5 months.Drug Susceptibility Testing. Drug susceptibility testing (DST) was performed using the Löwenstein-Jensen (L-J) proportion method (PM) [10]. The concentrations of drugs in L-J medium were as follows: 0.2 μg/ml for isoniazid (INH), 40 μg/ml for rifampicin (RIF), 2 μg/ml for ofloxacin (OFX), 30 μg/ml for kanamycin (KAN), 40 μg/ml for capreomycin (CAP), 40 μg/ml for prothionamide (PTO), 1 μg/ml for p-aminosalicylic acid (PAS), and 30 μg/ml for amikacin (AMK) [11, 12]. Results were read 28 days after inoculation and the referenceM.tb H37Rv strain was used as a control. A strain was declared resistant to an antimicrobial agent when the growth rate exceeded 1% compared with the control. The MDR-TB strains were defined as those resistant to both isoniazid and rifampicin. In addition, Pre-XDR-TB is defined as MDR-TB with additional resistance to either a fluoroquinolone (FQ) or an injectable (kanamycin, amikacin, or capreomycin), but not to both a FQ and an injectable, and XDR-TB resistant to any fluoroquinolone, and at least one of three second-line injectable drugs (capreomycin, kanamycin, and amikacin), in addition to MDR [11, 12].DNA Extraction and Amplification. The colonies from the surface of L-J medium were suspended in 500 μl Tris-EDTA (TE) buffer and heated in a 95°C water bath for 1 h. Genomic gene was extracted by a conventional method [13]. The DNA was used as template for amplification and the primers were shown in Table 1. The 50 μL PCR mixture was prepared as follows: 25 μl, 2x GoldStar MasterMix (CWBio, Beijing, China), 5 μL DNA template, and 0.2 μM of each primer set. PCR parameters for amplification were 5 min at 94°C, followed by 35 cycles at 94°C for 1 min, 58°C for 1 min, 72°C for 1 min, and a final extension at 72°C for 10 min. PCR products were sent to Tsingke company for sequencing. All sequences were aligned withgyrA,gyrB, rrs,andeis of the reference strain H37Rv (ATCC27294) using BioEdit (version 7.1.3.0) software.Table 1
The Primers used for PCR.
Symbol
Gene ID
Primers
PCR
Tm
Product length
gyrA
887105
F: 5′-TCGACTATGCGATGAGCGTG-3′
415 bp
58°C
R: 5′-GGTAGCACCGTCGGCTCTTG-3′
gyrB
887081
F: 5′-GAGTTGGTGCGGCGTAAGAGC-3′
322 bp
60°C
R: 5′-CGGCCATCAAGCACGATCTTG-3′
rrs
2700429
F: 5′-GAGTTGGTGCGGCGTAAGAGC-3′
464 bp
58°C
R: 5′-GGGGCGTTTTCGTGGTGCTCC-3′
eis
885903
F: 5′-GCGTAACGTCACGGCGAAATTC-3′
567 bp
60°C
R: 5′-GTCAGCTCATGCAAGGTG-3′Statistical Analysis. Chi square test was used to evaluate the associations among multiple categorical variables, and the statistical results were summarized with odds ratios (ORs) with 95% confidence intervals (CIs). And Fisher’s exact test was used if any expected counts are less than 5. All calculations were performed in SPSS 13.0 (SPSS Inc., USA).


## 3. Results

Demographic Characteristics and Drug Susceptibility Profiles. A total of 156 (23.0%) of 677 clinical isolates were identified as MDR-TB, including 53 (34.0%) pre-XDR and 20 (12.8%) XDR. Overall, 121 (77.6%) strains were isolated from male patients and 35 (22.4%) from female patients. The average age of the patients was 47.5 years old (range 15–80 years), and the patients in 60–69 years old group had a significantly lower risk of resistance to the SLDs than those in other groups (OR, 4.533; 95%CI, 1.303 to 15.772; P=0.014) (Table 2). In addition, 79 (50.6%) of isolates were from urban areas (within an hour drive from the downtown) of Chongqing and 77 (49.4%) were from suburb. The retreated case were 85 (54.5%) which occupied the large proportion. Compared with the previously treated failure group, the retreatment failure group had greater risk of second-line-drug resistance (P<0.05) (Table 2).Table 2
Risk factors of second-line drug resistance among 156MDRa isolates.
Characteristics
Number (%) of isolates (n=156)
Number (%) of isolates
OR (95% CI)
P
R
e
s
i
s
t
a
n
t
b
S
u
s
c
e
p
t
i
b
l
e
c
Sex
Female
35 (22.4)
21 (25.9)
14 (18.6)
—
—
Male
121 (77.6)
60 (74.1)
61 (81.3)
1.356 (0.635–2.894)
0.431
Age
~29
29 (18.6)
17 (21.0)
12 (16.0)
—
—
30~39
33 (21.2)
19 (23.5)
14 (18.7)
1.044 (0.380–2.870)
0.934
40~49
40 (25.6)
19 (23.5)
21 (28.0)
1.566 (0.597–4.110)
0.361
50~59
25 (16.0)
16 (19.8)
9 (12.0)
0.797 (0.265–2.397)
0.686
60~69
21 (13.5)
5 (6.2)
16 (21.3)
4.533 (1.303–15.772)
0.014
≧70
8 (5.1)
5 (6.2)
3 (4.0)
0.850 (0.170–4.256)
1.000
h
District
Urban
79 (50.6)
36 (44.4)
43 (57.3)
—
—
Suburb
77 (49.4)
45 (55.6)
32 (42.7)
0.595 (0.316–1.122)
0.108
Treatment history
Previously treated failurecasesd
18 (11.5)
6 (7.4)
12 (16.0)
—
—
Previously treatedcasese
30 (19.2)
18 (22.2)
12 (16.0)
0.333 (0.098–1.132)
0.074
Retreatment failurecasesf
23 (14.7)
15 (18.5)
8 (10.7)
0.267 (0.072–0.9814)
0.043
Retreatmentcasesg
85 (54.5)
42 (51.9)
43 (57.3)
0.512 (0.176–1.490)
0.214
M
D
R
a is defined as Mycobacterium tuberculosis strain resistant to at least isoniazid and rifampin. Theb isolate strain is resistant to one of the second-line drugs as follows: OFX, KAN, AMK, CAP, PTO, or PAS; Thec isolate strain is susceptible to all of the second-line drugs as follows: OFX, KAN, AMK, CAP, PTO, and PAS. dPreviously treated failure cases, still sputum smear-positive after the whole treatment (6 months) or treatment for 5 months. ePreviously treated cases, still sputum smear-positive at the end of 3-month treatment. fRetreatment failure case, still sputum smear-positive after the whole treatment (9 months) or treatment for 5 months. gRetreatment cases, who were once cured but relapsed or were treated more than 1 month but treatment interruption was longer than 2 months; now accept treatment again; Ph value from Fisher’s exact test.Second-Line Anti-TB Drug-Resistant Pattern. Table 3 described the distribution of the 156 MDR isolates according to second-line-drug-resistant patterns. We identified 2 groups of MDR isolates: (i) those with resistance to one of the SLDs included OFX, KAN, CAP, PTO, PAS, and AMK (monoresistant) and (ii) those with resistance to more than one of the SLDs mentioned above (multiresistant). And there were 81 isolates resistant to at least one of the six second-line anti-TB drugs among 156 MDR isolates. The most predominant pattern was monoresistant to OFX (34/156, 21.79%). Combining the number of monoresistant and multiresistant isolates and calculating their percentages with respect to the 156 MDR-TB isolates, the rates of general resistance to each of the drugs were as follows: OFX (66/156, 42.3%), KAN (26/156, 16.7%), CAP (13/156, 8.3%), PTO (11/156, 7.1%), PAS (22/156, 14.1%), and AMK (20/156, 12.8%) (Figure 1). Furthermore, compared with KAN, CAP, PTO, PAS, or AMK, OFX is more likely to be the second-line drug resistance by the MDR isolates (P<0.001). In addition, comparing the resistance rate of KAN with CAP or PTO, as well as PTO with PAS, also had significant difference (P<0.05) (Figure 1).Table 3
Patterns of drug resistance to second-linea drugs among 156 MDRb isolates from Southwest of China.
Patterns
Number of isolates (n=156)
Number (%)
Monoresistant
43
27.56
OFX
34
21.79
KAN
1
0.64
PTO
2
1.28
PAS
6
3.85
Multiresistant
38
24.36
OFX + KAN
3
1.92
OFX + KAN + AMK
2
1.28
OFX + KAN + CAP
1
0.64
OFX + KAN + PAS
1
0.64
OFX + KAN + CAP + AMK
4
2.56
OFX + KAN + PTO + AMK
1
0.64
OFX + KAN + PTO + PAS + AMK
1
0.64
OFX + KAN + CAP + PAS + AMK
5
3.21
OFX + KAN + CAP + PTO + PAS + AMK
1
0.64
OFX + AMK
1
0.64
OFX + PTO
5
3.21
OFX + PAS
7
4.49
KAN + AMK
2
1.28
KAN + CAP + AMK
2
1.28
KAN + PTO + AMK
1
0.64
KAN + PAS
1
0.64
Susceptible
75
48.08
T
h
e
a second-line drugs are as follows: OFX, KAN, AMK, CAP, PTO, or PAS; MDRb is defined as Mycobacterium tuberculosis strains resistant to at least isoniazid and rifampin.Figure 1
Distribution of MDR isolates resistant to different second-line drugs.Compareda with OFX group, P<0.001. Comparedb with KAN group, P<0.05. Comparedc with PTO group, P<0.05.Risk Factors for the Pre-XDR-TB/XDR-TB from 156 MDR Isolates from Southwest of China. As expected, the age and the district maybe independent factors associated with Pre-XDR-TB/XDR-TB isolates. Patients whose age is between 60 and 69 had a significantly lower risk of being a Pre-XDR-TB or XDR-TB cases than those at other ages (OR, 4.554; 95% CI, 1.228 to 16.881; P=0.037) (Table 4).Table 4
The effect of age on the Pre-XDR/XDR isolates from Southwest of China.
Age
Number (%) of isolates (n=156)
Number (%) of Pre-XDR/XDR isolates (n=73)
OR (95% CI)
P
~29
29 (18.6)
15 (20.5)
—
—
30~39
33 (21.2)
18 (24.7)
0.893 (0.328–2.427)
0.824
40~49
40 (25.6)
17 (23.3)
1.450 (0.554–3.790)
0.446
50~59
25 (16.0)
14 (19.2)
0.842 (0.288–2.465)
0.753
60~69
21 (13.5)
4 (5.5)
4.554 (1.228–16.881)
0.037
a
≧70
8 (5.1)
5 (6.8)
0.643 (0.128–3.203)
0.588
P
a value from Fisher’s exact test.OFX Resistance with gyrA or gyrB Mutation. Because known mechanisms of FQ resistance are caused by mutations in the quinolone resistant-determining region (QRDR) of the gene encoding subunit A or B of DNA gyrase (gyrA orgyrB), fragments comprising these regions were analyzed in this study. Among 156 MDR-TB isolates, 66 were resistant to OFX. Of them, 53 isolates (80.2%) contained mutations withingyrA (Table 5). The most predominant mutations occurred at codon 94 (34 isolates, 64.2%), where the Asp codon was replaced with a Gly (15 isolates, 28.3%), Ala (12 isolates, 22.6%), Tyr (1 isolates, 1.9%), or Asn (6 isolates, 11.3%) codon. The Asp94 mutations were also found in four combinations: one with an Ala74Ser mutation and three with an Ala90Val mutation. The Ala90Val mutation was the secondly predominant mutation (16 isolates, 30.2%). The Ala90 mutations were also found in three combinations: one with Gly88Ala mutation, one with an Asp94Gly mutation, and two with Asp94Ala mutation. Other mutations withingyrA included Gly88Cys (n=1), Asp89Asn (n=1), and Ser91Pro (n=3). Mutations withingyrB were observed in four isolates (6.1%), with Asp461Asn (n=1), and Gly512Arg (n=3). Nine strains of OFX-susceptible isolates also display mutations within these two target fragments. Among them, the mutations withingyrA included Gly88Ala (n=1), Ala90Val (n=2), and Asp94Ala (n=2) and mutations withingyrB were observed in four isolates with Asp461Asn (n=3), and Gly512Arg (n=1) (Table 5).Table 5
The characteristics ofgyrA and gyrBgene mutations in 156 MDR isolates.
(Number of isolates)
Locus
Codon/nucleotide change(s)
Aminoacidb/nucleotide change(s)
Number of strains
Number (%)
OFX-resistant (66)
gyrA
NM
NM
13
19.7
GGC→TGC
Gly88Cys
1
1.5
GAC→AAC
Asp89Asn
1
1.5
GCG→GTG
Ala90Val
13
19.7
TCG→CCG
Ser91Pro
3
4.5
GAC→AAC
Asp94Asn
6
9.1
GAC→GCC
Asp94Ala
10
15.2
GAC→GGC
Asp94Gly
13
19.7
GAC→TAC
Asp94Tyr
1
1.5
GCC→TCC/GAC→GGC
Ala74Ser/Asp94Gly
1
1.5
GCG→GTG/GAC→GCC
Ala90Val/Asp94Ala
2
3.0
GCG→GTG/GAC→GGC
Ala90Val/Asp94Gly
1
1.5
GGC→GCC/GCG→GTG
Gly88Ala/Ala90Val
1
1.5
gyrB
NM
NM
62
93.9
GAC→AAC
Asp461Asn
1
1.5
GGG→AGG
Gly512Arg
3
4.5
OFX-susceptible (90)
gyrA
NM
NM
85
94.4
GGC→GCC
Gly88Ala
1
1.1
GCG→GTG
Ala90Val
2
2.2
GAC→GCC
Asp94Ala
2
2.2
gyrB
NM
NM
86
95.6
GAC→AAC
Asp461Asn
3
3.3
GGG→AGG
Gly512Arg
1
1.1
KAN-resistant (26)
rrs
NM
NM
7
26.9
G→A
G1339A
1
3.8
A→G
A1401G
18
69.2
eis
NM
NM
22
84.6
G→A
G(−10)A
3
11.5
C→T
C(−14)T
1
3.8
KAN-susceptible (130)
rrs
NM
NM
129
99.2
A→G
A(1449)G
1
0.8
eis
NM
NM
129
99.2
G→A
G(−10)A
1
0.8
NM, no mutation;Aminob acid numbers are based on homologous mutations inEscherichia coli.KAN Resistance with eis or rrs Mutations. Since resistance to KAN is caused by mutations inrrs or the promoter ofeis, a 516-bp region of the open reading frame ofrrs and the promoter ofeis were investigated. Among all 156 MDR-TB isolates, 26 isolates were resistant to KAN, and 19 (88.5%) of these contained mutations within therrs and 4 (15.4%) withineis region of interest, respectively (Table 6). None of the isolates contained mutations within both loci. The most frequent mutation ofrrs region was A1401G, which was observed in 18 isolates (69.2%), as a single mutation. The other mutation withinrrs region was G1339A (n=1). Mutations within the promoter region ofeis included the G(-10)A (n=3) and C(-14)T (n=1). We also found two KAN-susceptible MDR isolates harboring a A(1449)G mutation inrrs region and a G(-10)A mutation in the promoter ofeis, respectively (Table 5).Table 6
The relationship between gene mutation and drug resistance in 156 MDR isolates.
Drug-resistant phenotype
Number of isolates
Locus
Number (%) of isolates
χ
2
P
Mutation
Without mutation
OFX
gyrA
Resistant
66
53 (80.3)
13 (19.7)
91.086
<0.001
Susceptible
90
5 (5.6)
85 (94.4)
gyrB
Resistant
66
4 (6.1)
62 (93.9)
0.007
0.932a
Susceptible
90
4 (4.4)
86 (95.6)
KAN
rrs
Resistant
26
19 (73.1)
7 (26.9)
<0.001b
Susceptible
130
1 (0.8)
129 (99.2)
eis
Resistant
26
4 (15.4)
22 (84.6)
0.003b
Susceptible
130
1 (0.8)
129 (99.2)
C
o
n
t
i
n
i
t
y
a correction; Fbisher’s exact test.Association of Gene Mutation and Drug Resistance among 156 MDR-TB Isolates. Table 6 showed that the isolates withgyrA gene mutation were closely related to the drug resistance to OFX (P<0.001). In contrast, there was no significant difference in the proportion of isolates with mutations ingyrB gene between OFX-resistant and OFX-susceptible isolates. In addition, the isolates withrrs oreis gene mutation also had something to do with the drug resistance to KAN (P<0.001, P=0.003, resp.).


## 4. Discussion

TB is an underappreciated public health threat in developed nations. In 2015, an estimated 10.4 million new TB cases and 1.4 million deaths occurred worldwide; and 3.9% of these new cases were multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) strains [1]. Drug resistance is a severe challenge to tuberculosis control, as it raises the possibility of a condition that can no longer effectively be treated with antituberculosis drugs and further transmission to public population [14]. This situation of MDR-TB highlights the urgent need for rapid and accurate drug susceptibility testing (DST) to optimize the treatment regimen and reduce the risk of acquired resistance [15]. Despite China having the second highest incidence of MDR-TB, information regarding MDR-TB and resistance to second-line antituberculosis drugs (SLDs) among MDR-TB isolates still remains unclear for many regions of China. This study is the first to detect SLDs resistance among MDR-TB isolates in Chongqing, Which is a very important city in Southwest of China.Because of the diversity of TB epidemical situation, the actual use of SLDs, and other factors, the rate of SLDs resistance would be distinctive in different regions. This study showed that 51.9% of MDR-TB patients in Chongqing had resistance to at least one SLDs, which is slightly lower than Shanghai (54.4%) [16], another city of China, even worse than that in other reports, India (44.8%) [17], Russia (43.3%) [18], and Poland (30.4%) [19]. This indicated that the situation of SLDs resistance in this region is serious.The results showed that the retreatment failure group had greater risk of SLDs resistance than previously treated failure group. As the patients in the retreatment failure group with a longer history of SLDs treatment were more likely to have isolates resistant to the drugs. This association, to some degree, could reflect the poor administration of drugs in health facilities, where some SLDs, such as fluoroquinolones (FQs), are easily and extensively prescribed for respiratory infections and other bacterial infections and in some cases even available without a prescription in local drug stories. Easy access and inappropriate use of these drugs increase the risk for the emergence of drug-resistant TB. Meanwhile our results implied the rate of resistance to OFX (42.3%) in MDR-TB isolates is highest among the six SLDs. This may be due to OFX as one of the main FQs has been extensively used for TB or other disease and the transmission of OFX-resistantM.tb directly in China; therefore this should be considered whether it is an optimal regimen for MDR-TB treatment in China.Generally speaking, the demographic characteristics including the medical conditions and socioeconomic factors were related to the occurrence of tuberculosis resistance [5, 20]. Chongqing is located in Southwest of China and contains 39 districts and counties, of which 14 state-level poverty-stricken areas are in the “suburbs,” and has a high incidence of tuberculosis. However, this result showed that there was no statistical difference of SLDs-resistant MDR-TB isolates between urban areas and suburb. Maybe with the implementation of urban and rural development strategy of Chongqing, traffic is more convenient and population mobility is greater, so the occurrence of TB within the city is likely to spread. And reports revealed that SLDs-resistant TB arises mainly from direct transmission [16, 20–23]. On the other side, XDR-TB isolates in our study were significantly more in suburb (5.1%, 4/79) than those in urban areas (20.8%, 16/77) (P=0.004). The main reason for this is that the people living in the suburb usually have poorer economic level, education level, and medical level than those in the urban areas. Therefore they also have inadequate knowledge of TB so that they have poor compliance of treatment and high rates of irregular medication.An interesting finding of our study is that patients 60–69 years old had a significantly lower risk of SLDs resistance (P<0.05) and also had a lower rate of Pre-XDR-TB/XDR-TB (P<0.05) than those of other age. This result is consistent with another report of China [24] and a conclusion of review from European studies [25]. Although the exact reason is unknown, we hypothesize that the increased risk of harboring SLD resistance in patients under 60 years may be due to the previously exposure of SLDs, such as OFX which was uesd for anti-TB treatment from around 1985 in Chongqing; TB cases in older patients are usually considered as relapse cases, and the infecting strains may be more ancient and carry a lower risk of becoming resistant to OFX, which is associated with the emergence of resistance to SLDs among this special population.OFX as one of FQs plays an important role in the treatment of various types of drug-resistant TB. FQs mainly act on the DNA gyrase in order to interfere DNA replication leading to bacterial death. The DNA gyrase is a tetramer composed of two A and two B subunits which are encoded by thegyrA andgyrB genes, respectively. The quinolone resistant-determining region (QRDR) is comprised of conserved area withingyrA andgyrB gene [26, 27]. It has been reported that mutations ofgyrA gene inM.tbare closely related to quinolone resistance, while the mutations ofgyrB gene are seldom related to the drug resistance [26–29]. Our results are consistent with these researches. The isolates of MDR-TB with mutations ofgyrA gene were closely related to the drug resistance to OFX (P<0.001). As comparison there were 90 cases which were selected from 521 non-MDR-TB cases randomly (data not shown), among which there were 84 OFX-susceptible strains and only one strain with the mutation ofgyrA gene (1.2%); 6 OFX-resistant strains also contain one strain with mutation ofgyrA gene (16.7%). In contrast, no significant correlation between OFX resistance andgyrB polymorphism was observed in this study. Hence, detection of the mutation ofgyrA gene could be used to predict OFX resistance in Chongqing. Notably, there were 13 OFX-resistant strains without mutation located ingyrA, indicating that there are other mechanisms related to OFX resistance, such as cell wall permeability and drug efflux pump [30, 31]. On the other hand, there were 5 OFX-susceptible strains with mutation ofgyrA gene, including one strain with an Gly88Ala mutation, two strains with Ala90Val mutation, and two strains with Asp94Ala mutation, respectively. These mutant types may be associated with low-level OFX resistance, which will be evaluated by MIC method in the future.KAN is another one of important antituberculosis SLDs. It plays a role in inhibiting protein synthesis by 16SrRNA. And 16SrRNA is encoded byrrs gene whose mutation is currently known as the main mechanism of KAN resistance. Among them, the 1401 A → G point mutation is considered to be an important symbol of high-level resistance to KAN [32, 33]. Our observation is in agreement with these reports; 26 isolates were resistant to KAN, and 19 of these (73.1%) contained mutations within therrs region. The most common mutation ofrrs gene was A1401G, which was observed in 18 isolates (69.2%), as a single mutation. Interestingly, there was one KAN-resistant strain harboring G1339A substitution located inrrsregion, which may serve as another mechanism contributing to KAN resistance. Besidesrrs, the mutations in the promoter region ofeis gene were associated with low-level resistance to KAN [34]. The most common mutation points ineis gene reported were the G(-10)A and C(-14)T. Our study supports these findings, as 4 isolates were found to have mutations ineisgene, including three of G(-10)A and one of C(-14)T. Thus, among 26 KAN-resistant isolates, 20 isolates (76.9%) contained mutations in eitherrrs or (and)eis gene, and 3 isolates contained mutations in both of the genes. This suggested that the sequencing ofrrs andeis region could be a rapid filter method for KAN resistance before the DST results. And combining detection of the two regions might improve the sensitivity and accuracy of the drug resistance to KAN.There were several limitations of this study. First, the present study only enrolled the previously treated TB patients rather than new cases due to the limitation in cost and human resource. Thus, we could not describe the drug-resistant profiles against SLDs among this population. Second, although a large number of clinical MDR-TB isolates were tested (n=156), the number of SLDs-resistant isolates, especially OFX- resistant (n=66) and KAN-resistant (n=26) isolates, was still small. This might limit the detection of the variety of gene mutations. Third, there was still some drug-resistant isolates that could not be explained in our study, such as mutations at other gene regions [35], permeability of cell membrane, and overexpression of drug efflux pump gene [30, 31]. Therefore the other mechanisms of OFX resistance or KAN resistance will be detected in the further study and whole-genome sequencing might be needed to find more loci associated with drug resistance and to improve the performance of the sequencing-based assay.In conclusion, our data indicated that 51.9% MDR-TB patients in Southwest of China were resistant to at least one of SLDs, and most of which were resistant to OFX (42.3%) and KAN (16.7%). The mutation ofgyrA gene inM.tb is mainly mechanisms of OFX resistance. In addition, the mutation ofrrs gene and the promoter ofeis gene also have a close relationship with KAN resistance. Therefore the improper use of SLDs especially OFX for other infections is a real threat to effective MDR-TB treatment and OFX may be not an optimal regimen for MDR-TB patients. At present in China, the commercial drug-resistant test kits for screening target gene mutation are mainly on the first-line anti-TB drugs. However, the detection of gene mutations associated with the SLDs resistance has not yet been made universal. In addition to gene sequencing, the development of commercial kits for rapid molecular diagnosis of the SLDs-resistant-related genes is urgently needed to assist in controlling these severe forms of MDR-TB.



---

*Source: 4563826-2017-07-17.xml*